CY1115552T1 - Σταθερα σκευασματα μπορτεζομιμπης - Google Patents

Σταθερα σκευασματα μπορτεζομιμπης

Info

Publication number
CY1115552T1
CY1115552T1 CY20141100654T CY141100654T CY1115552T1 CY 1115552 T1 CY1115552 T1 CY 1115552T1 CY 20141100654 T CY20141100654 T CY 20141100654T CY 141100654 T CY141100654 T CY 141100654T CY 1115552 T1 CY1115552 T1 CY 1115552T1
Authority
CY
Cyprus
Prior art keywords
bortezomib
borzezombi
preparations
stable
lewis
Prior art date
Application number
CY20141100654T
Other languages
English (en)
Inventor
Kumaresh Soppimath
Satish Pejaver
Kanaiyalal R Patel
Lakkaraju Dasaradhi
Rama Sodum
Hari Desu
Navneet Puri
Original Assignee
Innopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/431,313 external-priority patent/US8263578B2/en
Application filed by Innopharma, Inc. filed Critical Innopharma, Inc.
Publication of CY1115552T1 publication Critical patent/CY1115552T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Παρουσιάζονται σκευάσματα πολλαπλής δόσης για μπορτεζομίμπη στα οποία η μπορτεζομίμπη έχει σημαντικά βελτιωμένη σταθερότητα. Ιδιαίτερα προτιμώμενα σκευάσματα περιλαμβάνουν αυτά στα οποία η μπορτεζομίμπη είναι σε μια υγρή μορφή κατάλληλη για έγχυση, όπου το σύστημα διαλύτη κυρίως περιλαμβάνει προπυλενο γλυκόλη. Σε άλλες προτιμώμενες απόψεις, η μπορτεζομίμπη είναι παρούσα ως ένα σύμπλοκο δότη-αποδέκτη κατά Lewis με μια ετερο-διλειτουργική βάση κατά Lewis.
CY20141100654T 2012-03-27 2014-08-14 Σταθερα σκευασματα μπορτεζομιμπης CY1115552T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/431,313 US8263578B2 (en) 2010-03-18 2012-03-27 Stable bortezomib formulations
EP12183276.0A EP2644189B1 (en) 2012-03-27 2012-09-06 Stable bortezomib formulations

Publications (1)

Publication Number Publication Date
CY1115552T1 true CY1115552T1 (el) 2017-01-04

Family

ID=46832244

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100654T CY1115552T1 (el) 2012-03-27 2014-08-14 Σταθερα σκευασματα μπορτεζομιμπης

Country Status (9)

Country Link
EP (1) EP2644189B1 (el)
JP (1) JP5774561B2 (el)
CA (1) CA2784240C (el)
CY (1) CY1115552T1 (el)
DK (1) DK2644189T3 (el)
ES (1) ES2497665T3 (el)
PL (1) PL2644189T4 (el)
PT (1) PT2644189E (el)
SI (1) SI2644189T1 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2866135A1 (en) 2012-03-02 2014-09-06 Dr. Reddy's Laboratories Limited Pharmaceutical compositions comprising boronic acid compounds
WO2016001905A2 (en) * 2014-07-04 2016-01-07 Dr. Reddy’S Laboratories Limited Stable liquid ready-to-use injectable formulation of bortezomib
EP3120836A1 (de) * 2015-07-22 2017-01-25 Stada Arzneimittel Ag Gebrauchsfertige bortezomib-lösung
EP3120837A1 (de) * 2015-07-22 2017-01-25 Stada Arzneimittel Ag Verfahren zur herstellung einer bortezomibester-lösung
KR101807462B1 (ko) 2017-03-09 2017-12-08 씨제이헬스케어 주식회사 보르테조밉을 포함하는 안정한 제제 및 이의 제조방법
CN109320584A (zh) * 2017-08-01 2019-02-12 重庆医药工业研究院有限责任公司 一种硼替佐米的杂质及其制备方法
JP7036602B2 (ja) * 2018-01-18 2022-03-15 日本化薬株式会社 ボルテゾミブを含有する医薬製剤の製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
CA2435124A1 (en) 2001-01-25 2002-08-01 Millennium Pharmaceuticals, Inc. Formulation of boronic acid compounds
CN101528037A (zh) * 2006-11-03 2009-09-09 默克公司 使用saha和硼替佐米治疗多发性骨髓瘤的方法
WO2008075376A1 (en) 2006-12-18 2008-06-26 Natco Pharma Limited Polymorphic forms of bortezomib and process for their preparation
GEP20135847B (en) 2008-06-17 2013-06-10 Millennium Pharm Inc Boronate ester compounds and pharmaceutical compositions containing them
EA201170527A1 (ru) 2008-10-01 2011-10-31 Др. Редди'С Лабораторис Лтд. Фармацевтические композиции, включающие соединения бороновой кислоты
KR20110114562A (ko) 2009-01-09 2011-10-19 썬 파마 어드밴스트 리서치 컴패니 리미티드 보르테조밉 함유 약학적 조성물
EP2238973A1 (en) * 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
WO2011116286A2 (en) * 2010-03-18 2011-09-22 Innopharma, Llc Stable bortezomib formulations

Also Published As

Publication number Publication date
JP2013203738A (ja) 2013-10-07
PL2644189T3 (pl) 2014-12-31
CA2784240A1 (en) 2013-09-27
DK2644189T3 (da) 2014-08-18
JP5774561B2 (ja) 2015-09-09
CA2784240C (en) 2014-07-08
SI2644189T1 (sl) 2014-10-30
EP2644189B1 (en) 2014-05-14
ES2497665T3 (es) 2014-09-23
PL2644189T4 (pl) 2015-04-30
PT2644189E (pt) 2014-08-29
EP2644189A1 (en) 2013-10-02

Similar Documents

Publication Publication Date Title
CY1115552T1 (el) Σταθερα σκευασματα μπορτεζομιμπης
CY1123675T1 (el) Πολυαιθυλενογλυκολιωμενου φαρμακου-συνδετες για βελτιωμενες φαρμακοκινητικες προϊοντος συζευξης προσδετη-φαρμακου
CY1121879T1 (el) Συνθεσεις και μεθοδοι για διαμορφωση hbv και ttr εκφρασης
CY1123434T1 (el) Λυοφιλοποiημενα νανοεναιωρηματα φαρμακων
CY1124431T1 (el) Συριγγα
CL2017003316A1 (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen.
BR112016026291A2 (pt) Derivados do ácido borônico e usos terapêuticos dos mesmos
ECSP17083003A (es) Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen
CY1116192T1 (el) Πυρρολοβενζοδιαζεπινες και συζευγματα αυτων
CY1118735T1 (el) Παραγωγα βενζιμιδαζολο-προλινης
CY1120173T1 (el) Ενωση πυραζολο-αμιδιου και φαρμακευτικες χρησεις αυτης
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
WO2011116286A3 (en) Stable bortezomib formulations
CY1121881T1 (el) Φαρμακοτεχνικη μορφη που περιεχει σταθερη αναλογια ινσουλινης glargine/λιξισενατιδης
CR20140525A (es) Compuestos de N-alquiltriazol como antagonistas de LPAR
CY1118323T1 (el) Ρυθμιστες του ηπατικου υποδοχεα χ
MX2018001511A (es) Polimeros furtivos desordenados de forma intrinseca codificados geneticamente para suministro y metodos para usar los mismos.
CL2017000984A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas
UY34582A (es) Anticuerpos anti-cxcr3
TR201821285T4 (tr) CCR3 antagonisti içeren farmasötik formülasyonlar.
MX2016015010A (es) Composiciones para el cuidado bucal que contienen polietilenglicol para estabilidad fisica.
CY1123720T1 (el) Συνθεσεις ενος πολυορθοεστερα και ενος εκδοχου οργανικου οξεος
ES2552754T1 (es) Formulaciones de daptomicina y usos de la misma
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
AR099132A1 (es) Colorante-polímero